Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Selective control of gene expression by CDK9 in human cells.

Garriga J, Xie H, Obradovic Z, Graña X.

J Cell Physiol. 2010 Jan;222(1):200-8. doi: 10.1002/jcp.21938.


CDK9 inhibition strategy defines distinct sets of target genes.

Garriga J, Graña X.

BMC Res Notes. 2014 May 16;7:301. doi: 10.1186/1756-0500-7-301.


Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.

Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, Graña X.

Gene. 2007 Dec 15;405(1-2):65-78. Epub 2007 Sep 19.


Complex effects of flavopiridol on the expression of primary response genes.

Keskin H, Garriga J, Georlette D, Graña X.

Cell Div. 2012 Mar 29;7:11. doi: 10.1186/1747-1028-7-11.


Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.

Albert TK, Rigault C, Eickhoff J, Baumgart K, Antrecht C, Klebl B, Mittler G, Meisterernst M.

Br J Pharmacol. 2014 Jan;171(1):55-68. doi: 10.1111/bph.12408.


Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription.

Ou M, Sandri-Goldin RM.

PLoS One. 2013 Oct 18;8(10):e79007. doi: 10.1371/journal.pone.0079007. eCollection 2013.


Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription.

Sabò A, Lusic M, Cereseto A, Giacca M.

Mol Cell Biol. 2008 Apr;28(7):2201-12. doi: 10.1128/MCB.01557-07. Epub 2008 Feb 4.


The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.

Hou T, Ray S, Brasier AR.

J Biol Chem. 2007 Dec 21;282(51):37091-102. Epub 2007 Oct 23.


Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.

Caracciolo V, Laurenti G, Romano G, Carnevale V, Cimini AM, Crozier-Fitzgerald C, Gentile Warschauer E, Russo G, Giordano A.

Cell Cycle. 2012 Mar 15;11(6):1202-16. doi: 10.4161/cc.11.6.19663. Epub 2012 Mar 15.


Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II.

Napolitano G, Majello B, Licciardo P, Giordano A, Lania L.

Gene. 2000 Aug 22;254(1-2):139-45.


Mechanisms controlling CDK9 activity.

Marshall RM, Grana X.

Front Biosci. 2006 Sep 1;11:2598-613. Review.


Cellular control of gene expression by T-type cyclin/CDK9 complexes.

Garriga J, Graña X.

Gene. 2004 Aug 4;337:15-23. Review.


Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA.

Burger K, Mühl B, Rohrmoser M, Coordes B, Heidemann M, Kellner M, Gruber-Eber A, Heissmeyer V, Strässer K, Eick D.

J Biol Chem. 2013 Jul 19;288(29):21173-83. doi: 10.1074/jbc.M113.483719. Epub 2013 Jun 6.


Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.

Shan B, Zhuo Y, Chin D, Morris CA, Morris GF, Lasky JA.

J Biol Chem. 2005 Jan 14;280(2):1103-11. Epub 2004 Nov 4.


Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.

Yeh YY, Chen R, Hessler J, Mahoney E, Lehman AM, Heerema NA, Grever MR, Plunkett W, Byrd JC, Johnson AJ.

Oncotarget. 2015 Feb 20;6(5):2667-79.


The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition.

Albert TK, Antrecht C, Kremmer E, Meisterernst M.

PLoS One. 2016 Jan 8;11(1):e0146648. doi: 10.1371/journal.pone.0146648. eCollection 2016.


TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast.

Viladevall L, St Amour CV, Rosebrock A, Schneider S, Zhang C, Allen JJ, Shokat KM, Schwer B, Leatherwood JK, Fisher RP.

Mol Cell. 2009 Mar 27;33(6):738-51. doi: 10.1016/j.molcel.2009.01.029.

Supplemental Content

Support Center